Dr. Khorasani: Scientist & Surgeon


Minimal Scar Wound Repair  

Dr. Khorasani's dedication to his patients goes beyond the assurance of successful surgeries; his goal is to deliver outstanding results by discovering new ways to minimize the appearance of scarring. Studies have shown that fetal wounds heal without scarring thus Dr. Khorasani has focused his research on the molecular agents involved in fetal wound healing including the TGF family of molecules and Fibromodulin. He has invested his time and efforts towards investigating the environmental and intrinsic differences in adult wound repair.

Clinical Trials as Principal Investigator

Skin closure device study:

  • Zipline incision approximation vs. suture study
  • This is a multi-site prospective randomized study designed to evaluate user preferences for the Zipline 3 system vs. conventional suturing 

Laser treatment of post-surgical scars:

  • Scar analysis of post-surgical wounds treated with an ablative fractional CO2 laser
  • This is a prospective randomized study designed to evaluate the optimal treatment interval post surgery as well as the histological and genetic changes that occur in scar remodeling (IRB pending) 

Botox® treatment of post-surgical wounds: 

  • Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring: A Double Blinded, Randomized Controlled Trial
  • A randomized trial designed to evaluate the effect of prophylactic Botulinum Toxin on forehead scars

Oncologic Trials:

  • A prospective observational study of treatment patterns and effectiveness and safety outcomes in advanced basal cell carcinoma and basal cell carcinoma nevus syndrome patients
  • In Situ, Autologous Therapeutic Vaccination Against Solid Cancers with Intratumoral Hiltonol® (Poly-ICLC)
  • The Effect of BRAF Inhibition With Vemurafenib On The Innate and Adaptive Immune Systems in Patients With Unresectable Stage III or Stage IV Melanoma Expressing a V600 BRAF Mutation
  • Phase Ib/2 Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects with Previously Untreated, Unresectable Stage IIIb/IV Melanoma

View Dr. Khorasani's Publications

Services We Offer


Choose your preferred location